Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec AG has completed the single ascending dose component of the phase I clinical study evaluating its drug candidate EVT 101 for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
The study in 48 young healthy subjects, of whom 36 received EVT 101, showed that the drug was well absorbed, extremely well tolerated with no significant adverse events, and had a good pharmacokinetic profile consistent with once- or twice-daily oral dosing.
EVT 101 is a selective antagonist of the NMDA receptor. The positive safety profile of the drug suggested in this trial is significant as non-selective NMDA receptor antagonists are associated with an unfavorable side-effect profile.
The company has now moved the drug into the multiple ascending dose stage of the phase I study in both young and elderly volunteers. Evotec said that it expects to publish final results of the complete phase I trials for EVT 101 in the third quarter of 2006.